REG - Genus - Non-Executive Director Appointments

GenusAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251119:nRSS0523Ia&default-theme=true

RNS Number : 0523I  Genus PLC  19 November 2025

19 November 2025

Genus plc

("Genus" or the "Group")

Board Change: Non-Executive Director Appointments

 

Genus (LSE: GNS), a leading global animal genetics company, is pleased to
announce the appointment of Dr Celia Baxter to the Board as a Non-Executive
Director with effect from 19 November 2025, and the appointment of Dr Robert
Reiter as a Non-Executive Director with effect from 1 January 2026.

Dr Baxter has had extensive experience in people-driven, multisite,
manufacturing, services and distribution businesses across business sectors in
international FTSE 100 and FTSE 250 companies as well as Big Four consulting,
having worked in increasingly senior Human Resources roles at Ford Motor
Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil
plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter
has a PhD in Botany from Reading University and is currently a non-executive
director and remuneration committee chair of Volution Group plc, senior
independent director and remuneration committee chair of discoverIE Group plc,
and senior independent director and remuneration committee chair of Dowlais
Group plc.  She was previously a non-executive director of Senior plc, RHI
Magnesita NV and Bekaert SA.

Dr Baxter brings widespread global experience in Human Resources, Strategy,
Branding, Mergers and Acquisitions and Change Management.

Dr Reiter is a plant geneticist by training and spent his executive career
delivering innovative new technologies and products within crop agriculture,
having worked in E.I. DuPont de Nemours, followed by twenty years in
increasingly senior scientific and supply chain leadership roles at Monsanto.
Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger,
collaborating with Bayer to design a world-class agricultural R&D
organisation, overseeing an annual investment portfolio exceeding $2.3
billion. Following the acquisition of Monsanto, Bob became an Executive Vice
President leading Research & Development for the combined Bayer Crop
Science division, and integrated the two divisions with accountability of over
7,000 employees.

Their appointments follow an extensive search process using an external search
agency.

Commenting on the appointments, Iain Ferguson, Chair of Genus, said:

"We are delighted to welcome Celia and Bob to the Board. Celia brings a broad
range of commercial and strategic experience and knowledge, as well as a
detailed understanding of executive remuneration practice and reporting
requirements. Bob brings substantial genetics and gene editing technology
experience, and has a track record of translating scientific projects into
commercial opportunities."

For further information please contact:

Genus plc            Tel: +44 (0)1256 345 970

Iain Ferguson, Chair

Jorgen Kokke, Chief Executive Officer

Buchanan Burson             Tel: +44 (0)207 466 5000

Charles Ryland; Toto Berger; Sophie Wills; Verity Parker

About Genus

Genus is a world-leading animal genetics company. Genus creates advances to
animal breeding and genetic improvement by applying biotechnology and sells
added value products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently commercialised by
Genus in the dairy, beef and pork food production sectors.

Genus's worldwide sales are made in over seventy-five countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen,
embryos and breeding animals with superior genetics to those animals currently
in farms. Genus's customers' animals produce offspring with greater production
efficiency, and quality, and use these to supply the global dairy and meat
supply chains.

The Group's competitive edge has been created from the ownership and control
of proprietary lines of breeding animals, the biotechnology used to improve
them and its global supply chain, technical service and sales and distribution
network.

With headquarters in Basingstoke, United Kingdom, Genus companies operate in
over twenty-five countries on six continents, with research laboratories
located in Madison, Wisconsin, USA.

Regulatory Notes

Details of any payments to be made to Celia Baxter and Bob Reiter will be
disclosed in full in the Company's 2026 Directors' Remuneration Report.  Any
such terms will be consistent with the Company's approved Directors'
Remuneration Policy.

 

This announcement is made in accordance with Listing Rule 6.4.6R.   There
are no matters to be disclosed in connection with Listing Rule 6.4.8R (2) -
(6). The person responsible for making this announcement on behalf of the
Group is Lucie Grant (General Counsel and Company Secretary).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABPBFTMTABBBA



            Copyright 2019 Regulatory News Service, all rights reserved